1. Gergely R, Kovács I, Schneider M, et al. Mineralocorticoid abdominal antagonist treatment in bilateral chronic central serous abdominal: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017; 37:1084–91.
2. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008; 115:169–73.
Article
3. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous abdominal: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013; 41:201–14.
4. Herold TR, Prause K, Wolf A, et al. Spironolactone in the treatment of central serous chorioretinopathya case series. Graefes Arch Clin Exp Ophthalmol. 2014; 252:1985–91.
5. Herold TR, Rist K, Priglinger SG, et al. abdominal results and abdominal rates after spironolactone treatment in nonresolving abdominal serous abdominal (CSCR). Graefes Arch Clin Exp Ophthalmol. 2017; 255:221–9.
6. Kapoor KG, Wagner AL. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res. 2016; 56:17–22.
Article
7. Kweon EY. Factors influencing the effect of the intravitreal abdominal injection in patients with central serous chorioretinopathy. J Korean Opthalmol Soc. 2014; 55:391–5.
8. Koh KM, Kim JY, Kim JW, Choi MJ. The efficacy of intravitreal bevacizumab injection in patients with acute central serous chorioretinopathy. J Korean Opthalmol Soc. 2012; 53:781–5.
Article
9. Yeo YD, Kim JH, Kim YC, Kim KS. Photodynamic therapy and focal laser photocoagulation in chronic central serous choriretinopathy. J Korean Opthalmol Soc. 2016; 57:56–62.
10. Kim YS, Lee YH, Kim HS, et al. Comparison of therapeutic effect between half-energy photodynamic therapy and intravitreal abdominal injection in chronic central serous chorioretinopathy for 12 months. J Korean Opthalmol Soc. 2013; 54:1526–33.
11. Falavarjani KG, Amirsardari A, Habibi A, et al. Visual and abdominalal outcomes of spironolactone therapy in patients with chronic central serous chorioretinopathy. J Ophthalmic Vis Res. 2017; 12:281–9.
12. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012; 122:2672–9.
Article
13. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone upregulates ion and water channels in Müller glial cells. FASEB J. 2010; 24:3405–15.
Article
14. Ghadiali Q, Jung JJ, Yu S, et al. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina. 2016; 36:611–8.
15. Sun X, Shuai Y, Fang W, et al. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. 2018; 102:1060–5.
Article
16. Kim JA, Shin JY, Bae SH, et al. Comparison of choroidal abdominal change after photodynamic therapy and ranibizumab for chronic central serous chorioretinopathy. J Korean Opthalmol Soc. 2015; 56:205–12.
17. Park SY, Koh HJ, Kim YM. Correlation between optical coherence tomography and visual-acuity in chronic central serous abdominal treated with half dose photodynamic therapy. J Korean Opthalmol Soc. 2013; 54:1715–22.
18. Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous abdominal: a pilot study. Retina. 2013; 33:2096–102.
19. Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized abdominalled crossover study. Retina. 2015; 35:2505–15.
20. Lee JY, Kim DY, Lee EK, et al. Comparison of short-term clinical outcomes between oral spironolactone and observation in acute central serous chorioretinopathy. J Korean Opthalmol Soc. 2018; 59:511–8.
Article
21. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000; 57:1408–11.
Article